2. Academic Validation
  3. Integrated Multiomics Analysis and Experimental Validation Identify ITPRIPL1 as an Immunoregulatory and Prognostic Biomarker in Gastric Adenocarcinoma

Integrated Multiomics Analysis and Experimental Validation Identify ITPRIPL1 as an Immunoregulatory and Prognostic Biomarker in Gastric Adenocarcinoma

  • J Gastroenterol Hepatol. 2026 Jan;41(1):231-247. doi: 10.1111/jgh.70183.
Zixuan Jia 1 2,  Kangqiao Xiong 3,  You Zhou 4,  Rong Chen 2,  Daofeng Wang 1,  Shaohang Cai 5,  Wei Liao 1
Affiliations

Affiliations

  • 1 Intensive Care Unit, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • 2 First Division of Intensive Care Unit, First People's Hospital of Kashi, Kashi Prefecture, China.
  • 3 State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangdong Provincial Clinical Research Centre for Cancer, Department of Medical Oncology, Sun Yat-sen University Cancer Centre, Guangzhou, China.
  • 4 State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • 5 State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Key Laboratory of Infectious Diseases Research in South China, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.
PMID: 41365494 DOI: 10.1111/jgh.70183
Abstract

Background: Inositol 1,4,5-trisphosphate receptor-interacting protein-like 1 (ITPRIPL1) has been identified as an inhibitory ligand of CD3ε, but its role in stomach adenocarcinoma (STAD) remains unclear.

Aims: This study aims to elucidate the oncogenic and immunoregulatory roles of ITPRIPL1 in STAD.

Materials and methods: Integrative bioinformatic analyses, including transcriptomic and spatial transcriptomic data, were performed to assess ITPRIPL1 expression, prognostic relevance, and immune interactions. Experimental approaches, including proliferation, migration, and invasion assays, were used to validate the functional effects.

Results: We found that ITPRIPL1 was significantly upregulated in STAD and associated with an unfavorable prognosis. Although enriched in T cell activation pathways, ITPRIPL1-expressing tumor cells predominantly interacted with regulatory T cells (Tregs) and exhausted T cells (Tex), while showing limited communication with cytotoxic or naïve T cells. Spatial analyses revealed positive correlations between ITPRIPL1 expression and both tumor malignancy and T cell exhaustion signatures, but a negative correlation with CD274 expression. Functional assays confirmed the role of ITPRIPL1 in promoting tumor cell proliferation, migration, and invasion.

Discussion: Collectively, ITPRIPL1 promotes STAD progression by increasing tumor aggressiveness and fostering interactions with immunosuppressive T cell subsets.

Conclusion: These findings suggest that ITPRIPL1 is a potential prognostic marker and immunosuppressive target in STAD.

Keywords

ITPRIPL1; STAD; multiomics analyses; pan‐cancer.

Figures
Products